JAZZ - Jazz Pharma Q1 top line up 14%; earnings up 85% May, 07 2019 04:34 PM Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 results (): Revenues: 508.2 (+14.3%); Xyrem sales: 368.3 (+16.3%).More news on: Jazz Pharmaceuticals plc, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...